What is Zacks Small Cap’s Forecast for Azitra Q2 Earnings?

Azitra, Inc. (NYSEAMERICAN:AZTR) – Investment analysts at Zacks Small Cap issued their Q2 2025 earnings per share (EPS) estimates for shares of Azitra in a report released on Wednesday, May 21st. Zacks Small Cap analyst J. Vandermosten forecasts that the company will post earnings of ($0.21) per share for the quarter. The consensus estimate for Azitra’s current full-year earnings is ($2.78) per share. Zacks Small Cap also issued estimates for Azitra’s Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.22) EPS and FY2027 earnings at ($0.64) EPS.

Azitra Price Performance

Shares of AZTR stock opened at $0.30 on Thursday. The stock’s 50-day moving average is $0.30 and its 200 day moving average is $0.40. Azitra has a 1-year low of $0.23 and a 1-year high of $12.00.

Hedge Funds Weigh In On Azitra

An institutional investor recently raised its position in Azitra stock. Virtu Financial LLC raised its holdings in shares of Azitra, Inc. (NYSEAMERICAN:AZTR) by 196.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 63,180 shares of the company’s stock after acquiring an additional 41,866 shares during the period. Virtu Financial LLC owned approximately 0.83% of Azitra worth $27,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.16% of the company’s stock.

About Azitra

Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.